Synthesis of novel macrocyclic docetaxel analogues. Influence of their macrocyclic ring size on tubulin activity.

J Med Chem

Institut de Chimie des Substances Naturelles, CNRS, Avenue de la Terrasse, 91198 Gif sur Yvette Cedex, France.

Published: August 2003

This work describes the synthesis of a series of novel macrocyclic taxoids 3 and 3(H) designed to mimic the docetaxel solid-state ("nonpolar") conformation. These compounds, bearing 18-, 20-, 21-, and 22-membered rings connecting the C-2 OH and C-3' NH moieties, were constructed by ring-closing olefin metathesis of the taxoid-omega,omega'-dienes 4. Biological evaluation of these new taxoids showed that activity is dependent on the ring size, and only the 22-membered ring taxoid 3d exhibits significant tubulin binding. Synthesis of the open-chain analogues 7 and 7(H) and comparison of their biological activities with macrocyclic taxoids show that the carbon tether between C-2 OH and C-3' NH does not hamper tubulin binding. Computational studies of the conformational behavior of the macrocyclic taxoids 3 indicate that the 18-, 20-, and 21-membered-ring 3a-c adopt mainly conformations that are not recognized by tubulin. The most active taxoid 3d appears to adopt a conformation that is between the "nonpolar" and T-shaped forms.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm030770wDOI Listing

Publication Analysis

Top Keywords

macrocyclic taxoids
12
novel macrocyclic
8
ring size
8
18- 20-
8
c-2 c-3'
8
tubulin binding
8
macrocyclic
5
synthesis novel
4
macrocyclic docetaxel
4
docetaxel analogues
4

Similar Publications

Objectives: This study aimed to compare the relative efficacy of lorlatinib, an anaplastic lymphoma kinase-tyrosine kinase inhibitor, with chemotherapy, for patients with second-line or later advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. The endpoints of interest were overall survival (OS) and progression-free survival (PFS).

Methods: Evidence for lorlatinib was informed by the single-arm phase I/II trial B7461001.

View Article and Find Full Text PDF

Purpose: Although lorlatinib, the third generation of echinoderm microtubule protein 4-anaplastic lymphoma kinase (EML4-ALK) tyrosine kinase inhibitor (TKI), overcame the previous generation ALK-TKIs' drug resistance problems, but the mechanism of lorlatinib resistance remained unclear. Furthermore, optimal chemotherapy for lorlatinib-resistant non-small cell lung cancer (NSCLC) patients was still unknown.

Methods: A lorlatinib-resistant NSCLC cell line SNU-2535LR was generated by gradually increasing dose of lorlatinib to crizotinib-resistant cell line SNU-2535 in vitro.

View Article and Find Full Text PDF

A phytochemical investigation on the aerial parts of resulted in the isolation of 27 macrocyclic diterpenoids, including three previously unreported lathyrane derivatives, euphohelioscopoids A-C (-). Their structures were elucidated by spectroscopic data interpretation. Three jatrophanes, euphoscopin C (), euphorbiapene D (), and euphoheliosnoid A (), showed cytotoxicity against a paclitaxel-resistant A549 human lung cancer cell line with IC values of 6.

View Article and Find Full Text PDF

Paclitaxel (PTX), a widely used anticancer agent, is found in the inner bark of several Taxus species, although at such low levels that its extraction is ecologically unsustainable. Biotechnological platforms based on Taxus sp. cell cultures offer an eco-friendlier approach to PTX production, with yields that can be improved by elicitation.

View Article and Find Full Text PDF

A reply to "ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis".

Lung Cancer

December 2020

Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, 410013, China; The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China. Electronic address:

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!